December 13, 2011 — Toshiba America Medical Systems Inc. has introduced DICOM Radiation Dose Structured Report on all new Infinix-i vascular X-ray systems. The new feature automatically records radiation dose information from every X-ray event, from beginning to end, based on each pedal push administered by the clinician.

Steris and Toshiba America Medical Systems formed an alliance to offer advanced vascular, cardiovascular, pediatric and neurosurgical hybrid surgical suites to healthcare systems seeking the latest patient-focused interventions.

December 13, 2011 – Boston Scientific announced the U.S. launch of its Charger PTA Balloon Catheter, a 0.035-inch percutaneous transluminal angioplasty (PTA) balloon catheter designed for a wide range of peripheral angioplasty procedures.  The Charger PTA Balloon Catheter is Boston Scientific's third new peripheral balloon catheter introduced in 2011. 

December 12, 2011 – Hansen Medical UK Ltd., a subsidiary of Hansen Medical Inc., a developer of robotic technology for accurate 3-D control of catheter movement, announced a new multi-center worldwide survey evaluating the safety and efficacy of atrial fibrillation (AF) ablation by robotic navigation with the Sensei robotic catheter system. The abstract was presented by Luigi Di Biase, M.D., Ph.D., in a poster session at the American Heart Association Scientific Sessions 2011 at the Orange County Convention Center in Orlando, Florida on November 14th, 2011.

December 12, 2011 - CardioMEMS announced that the U.S. Food and Drug Administration's (FDA) Circulatory Systems Devices advisory panel voted against the Champion heart failure monitoring system. It is the first wireless, permanently implantable device that allows cardiologists to monitor heart failure (HF) patients from their homes. While the panel agreed with a 9-1 vote that the CardioMEMS technology is safe, the majority did not vote positively that the system is effective and that reasonable assurance of the risks associated with the device outweigh the potential clinical benefits of the technology.

Boston Scientific recently announced U.S. Food and Drug Administration (FDA) approval for the Promus Element Plus everolimus-eluting platinum chromium coronary stent system, the company's next-generation drug-eluting stent (DES) technology.  The Promus Element, designed to provide physicians improved DES performance in treating patients with coronary artery disease, is built on a platinum chromium (PtCr) platform with the DES market-leading everolimus drug.  The company plans to begin marketing the product in the United States immediately.

Subscribe to
© Copyright Wainscot Media. All Rights Reserved.
Subscribe Now